ICE Bioscience

ICE Bioscience was founded in 2010 as an Innovative CRO+ Explorer company. We specialize in early drug discovery services, spanning from target validation to the identification of pre-clinical candidates. Currently, ICE Bioscience offers a broad selection of off-the-shelf assays, including 100+ ion channels, 800+ Kinases/enzymes, 100+ GPCRs, and 40+ nuclear receptor assays, all accompanied by validation data and screening information. This comprehensive range of assays provides us with a competitive edge, as it covers a vast majority of druggable targets. Our company has established multiple platforms, encompassing Protein Engineering, Cell Line Development, Target Based Assays, Safety Pharmacology, Translational Biology, DMPK,...

In vitro pharmacology,dmpk,target based assays,kinase profiling,safety pharmacology,gpcr,electrophysiology,drug discovery,transporter,adme,custom assay development,ion channel,moa studies,cell based assays,biochemical assays,biophysical assays,and enzymology

Ice bioscience operates in the Biotechnology research industry.

Ice bioscience's revenue is 11m - 100m

Ice bioscience has 11 - 50 employees.